Novartis AG / Selexys Pharmaceuticals

Sickle Cell Disease (vaso-occlusive crises)

$2.1B US hemoglobinopathies revenue 2014 (Grand View Research, cited by BioPharma Dive)

Disease Overview

Sickle cell disease is an inherited red blood cell disorder in which abnormal hemoglobin causes erythrocytes to assume rigid sickle shapes that occlude microvasculature, producing severe pain crises (vaso-occlusive events), organ damage, and shortened life expectancy. SCD predominantly affects people of African, Hispanic, Mediterranean, and South Asian descent and remains chronically under-resourced, with vaso-occlusive crises the leading reason for SCD-related healthcare encounters.

Competitive Landscape

At deal time (Oct 2016) the SCD treatment armamentarium was thin: hydroxyurea (generic, since 1998) was the lone disease-modifying standard plus Emmaus's Endari (L-glutamine, FDA approved 2017). SelG1/crizanlizumab — a humanized anti-P-selectin mAb — represented a first-in-class biologic targeting the adhesion cascade driving vaso-occlusion. Phase 2 SUSTAIN data (presented at ASH Dec 2016) showed a 47% reduction in median annual VOC rate versus placebo, prompting Novartis to exercise its 2012 option for ~$665M. Crizanlizumab was approved as Adakveo in November 2019 with blockbuster expectations. The competitive set evolved aggressively post-deal: Global Blood Therapeutics' Oxbryta (voxelotor, approved 2019; later acquired by Pfizer for $5.4B in 2022 and withdrawn 2024 over safety) and Vertex/CRISPR's Casgevy gene-editing therapy (2023) reset the bar. Adakveo's confirmatory Phase 3 STAND trial missed its primary endpoint (2.5 vs 2.3 painful crises per year), triggering EMA marketing authorization revocation in August 2023. The deal looked strategically sound at signing but ultimately produced a US-only commercial asset with declining utility.